His main research concerns Antibacterial agent, Microbiology, Pharmacokinetics, Antibiotics and Pharmacodynamics. His research in Antibacterial agent intersects with topics in Anesthesia, Surgery, Meropenem, Tobramycin and Aminoglycoside. His Microbiology research is multidisciplinary, relying on both Pseudomonas aeruginosa, Klebsiella pneumoniae, In vivo and Staphylococcus aureus.
Pharmacokinetics is a subfield of Pharmacology that David P. Nicolau tackles. His study in Antibiotics is interdisciplinary in nature, drawing from both Area under the curve and Intensive care medicine. His Pharmacodynamics study combines topics from a wide range of disciplines, such as Telithromycin and Tazobactam.
The scientist’s investigation covers issues in Microbiology, Antibiotics, Pharmacokinetics, Pharmacodynamics and Antibacterial agent. David P. Nicolau interconnects Pseudomonas aeruginosa, Klebsiella pneumoniae, In vivo and Staphylococcus aureus in the investigation of issues within Microbiology. In his research, Antibiotic resistance is intimately related to Intensive care medicine, which falls under the overarching field of Antibiotics.
The various areas that he examines in his Pharmacokinetics study include Gastroenterology and Anesthesia. His Pharmacodynamics research is multidisciplinary, incorporating elements of Regimen, Minimum inhibitory concentration, Cephalosporin and Dosing. His Antibacterial agent research is multidisciplinary, incorporating perspectives in Aminoglycoside and Streptococcus pneumoniae.
David P. Nicolau mainly focuses on Microbiology, Pseudomonas aeruginosa, Meropenem, Pharmacokinetics and Pharmacodynamics. The Microbiology study combines topics in areas such as In vitro and In vivo. David P. Nicolau has included themes like Amikacin, Enterobacterales and Pneumonia in his Pseudomonas aeruginosa study.
The Pharmacokinetics portion of his research involves studies in Pharmacology and Internal medicine. David P. Nicolau works mostly in the field of Pharmacology, limiting it down to topics relating to Antimicrobial and, in certain cases, Antibiotic resistance, as a part of the same area of interest. In his study, Vancomycin and Intensive care medicine is strongly linked to Antibiotics, which falls under the umbrella field of Pharmacodynamics.
His scientific interests lie mostly in Microbiology, Pseudomonas aeruginosa, Meropenem, Pharmacodynamics and Antibiotics. David P. Nicolau combines subjects such as Klebsiella pneumoniae, In vitro and In vivo with his study of Microbiology. His Meropenem study combines topics in areas such as Ceftazidime, Aztreonam, Potency and Fosfomycin.
His Pharmacodynamics study results in a more complete grasp of Pharmacokinetics. His Pharmacokinetics study incorporates themes from Gastroenterology and Renal function. His studies deal with areas such as Vancomycin, Dosing and Intensive care medicine as well as Antibiotics.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Experience with a once-daily aminoglycoside program administered to 2,184 adult patients.
D P Nicolau;C D Freeman;P P Belliveau;C H Nightingale.
Antimicrobial Agents and Chemotherapy (1995)
Once-daily dosing of aminoglycosides: review and recommendations for clinical practice.
Collin D. Freeman;David P. Nicolau;Paul P. Belliveau;Charles H. Nightingale.
Journal of Antimicrobial Chemotherapy (1997)
Clinical Pharmacodynamics of Meropenem in Patients with Lower Respiratory Tract Infections
Chonghua Li;Xiaoli Du;Joseph L. Kuti;David P. Nicolau.
Antimicrobial Agents and Chemotherapy (2007)
Pharmacodynamic comparisons of levofloxacin, ciprofloxacin, and ampicillin against Streptococcus pneumoniae in an in vitro model of infection
Melinda K. Lacy;Wen Lu;Xiaowei Xu;Pamela R. Tessier.
Antimicrobial Agents and Chemotherapy (1999)
The pharmacodynamics of aminoglycosides
Melinda K. Lacy;David P. Nicolau;Charles H. Nightingale;Richard Quintiliani.
Clinical Infectious Diseases (1998)
Use of Monte Carlo simulation to design an optimized pharmacodynamic dosing strategy for meropenem.
Joseph L. Kuti;Prachi K. Dandekar;Charles H. Nightingale;David P. Nicolau.
The Journal of Clinical Pharmacology (2003)
Double-Carbapenem Therapy for Carbapenemase-Producing Klebsiella pneumoniae
Catharine C. Bulik;David P. Nicolau.
Antimicrobial Agents and Chemotherapy (2011)
Adherence to Highly Active Antiretroviral Therapy Predicts Virologic Outcome at an Inner-City Human Immunodeficiency Virus Clinic
JoCarol McNabb;Jack W. Ross;Kenneth Abriola;Christina Turley.
Clinical Infectious Diseases (2001)
Pharmacokinetic and Pharmacodynamic Properties of Meropenem
David P. Nicolau.
Clinical Infectious Diseases (2008)
Carbapenems: a potent class of antibiotics.
David P Nicolau.
Expert Opinion on Pharmacotherapy (2008)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: